Zum Artikel

Dr. Katharina Severin Investment Manager

Dr. Katharina SeverinInvestment Manager

Dr. Katharina Severin

Investment Manager

About me

Team Life Sciences & Chemistry
at HTGF since 2021

CV

Katharina Severin joined the Life Science Team in September of 2021. She was born and raised in the Ruhr area and spent time in the US and Asia during her education. Among these stays was a one-year research stay in the lab of Tom Rapoport at Harvard Medical School in Boston. Katharina obtained her PhD in Medical Biology and received numerous scholarships and awards, among them stipends from the German National Academic Foundation and the Christiane Nüsslein-Volhard Foundation. Through networking opportunities from these foundations and as an attendee of the Lindau Nobel Laureate Meeting, Katharina discovered and cultivated her passion for interdisciplinary scientific exchange. Her research findings mark a starting point for a novel therapeutic approach in the treatment of cancer. Katharina is fascinated by entrepreneurial questions and is passionate about bringing scientific results and genious business ideas to profitable ventures.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2025

Akribion Therapeutics

Oncology

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …

To the complete profileof Akribion Therapeutics
2024

Heidelberg Epignostix

Diagnostic

Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …

To the complete profileof Heidelberg Epignostix
2022

Phialogics

Immunology

Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in …

To the complete profileof Phialogics
2021

Smarterials Technology

Composite Materials & New Materials

Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists …

To the complete profileof Smarterials Technology
2021

cutanos

Drug Delivery

Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …

To the complete profileof cutanos
2021

FundaMental Pharma

Neurology

FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …

To the complete profileof FundaMental Pharma

Guided to exit

12 of 500 Companies

Recent posts

Last update 2 days ago
Zum Artikel

News

4. February 2025

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Zum Artikel

News

2. July 2024

DKFZ spin-off Epignostix raises €4.3m Seed round to commercialize diagnostic tumor classifier

Zum Artikel

News

19. April 2023

Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases